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Introduction
Following the original discovery in the late 1950s [2] , in recent years, interferon (IFN, 1a Figure   1 ) has gained recognition as a drug of choice for the treatment of many viral diseases and certain cancers [3] . Effective use of peptide and protein drugs in patients suffers from their instability in vivo, arising from rapid clearance rates, premature uptake by tissues (for instance the reticuloendothelial system), loss through the kidneys, and immunogenicity or antigenicity [4] . In order to prolong the plasma half-life of interferon a number of strategies have been employed, with the aim of increasing in vivo efficacy as well as reducing injection frequency hence helping to improve patients' life quality. Until now, conjugation of interferon with polyethylene glycol (PEG) has been the most successful approach. This, significantly reduces plasma interferon clearance and immunogenicity [4] .
In general, pegylation occurs randomly on the ε-amino group of surface lysine residues [4] , though, site-specific pegylation has also been reported [5, 6] . For more specific targeting, however, fusion technology to graft a protein specifically to the N-or C-terminal of a drug has been developed.
Albumin fusion to interferon is one such example [6, 7] . Most commonly, E. coli is the host of choice for the heterologous expression of recombinant proteins. Expression of eukaryotic proteins in a prokaryotic host such as E. coli leads, sometimes, to inclusion body formation requiring subsequent protein refolding. The presence of disulfide bridges in proteins makes their refolding a complex and delicate task, not tractable for multi-thiol-containing fusion partners such as albumin, which have been produced in yeast [7, 8] .
Our previous work has shown that the expression of the Met-IFN encoding-DNA in E. coli leads to the production of a heterogeneous mixture of three products. These are: (a) the direct translation product of the DNA retaining the N-terminal methionine (2 Figure 1) , (b) a species from which the methionyl residue has been removed by E. coli methionyl aminopeptidase to give the native interferon α-2b (1a, Figure 1 ) and (c) a species in which the N-terminal Cys residue of the latter contains an acetyl group (1b, Figure 1 ). In the present study two related problems have been addressed. We firstly avoid the aforementioned processing of the N-terminal of interferon α-2b, by introducing a Phe residue following the initiator N-terminal Met of interferon α-2b (3 Figure   1 ). Secondly, we constructed chimeras between interferon α-2b and human cytochrome b5 (4-6 Figure 1 ). Critically, cytochrome b5 contains no cysteine residues and thus the two disulfide bridges in the final product will be formed by the four cysteines of interferon α 2b. We tested fusions of cytochrome b5 at the carboxy-or amino-terminal of interferon α-2b. Construct 4, Interferon core, referring to interferon α-2b, is shown in blue, its Nand C-termini are emboldened and additions to N-terminal are shown by (-) numbers. Cytochrome b5 skeleton in the chimera is in red with the connecting residues (L-E) in black.
Results and Discussion

The N-terminal heterogeneity
Our previous study considering human Met-IFN engineering (structure 2 Figure 1 ) using E. coli, as a host, showed that the expressed protein consisted of three species: (a), IFN with an intact methionine (Met-IFN (2)), encoded by the DNA sequence, (b), IFN without its N terminal methionine (1a) formed by the action of host methionine aminopeptidase on the primary translation product of the gene (2) and (c), N-acetyl-IFN (1b) formed by the action of E. coli acetyl transferase on IFN (1a) itself.
We set out to prevent N-terminal heterogeneity taking several approaches. Unsuccessful approaches included engineering expression vectors that encoded Met-IFN, and methionine aminopeptidase aiming to convert the primary translation product into native IFN [9] . However, soon it became evident that the main cause of heterogeneity was the action of an acetyl transferase which, as we will see later, efficiently modified the IFN N-terminal amino group of Cys 1 .
Notwithstanding, this heterogeneity, through careful HPLC separation we were able to obtain homogeneous native IFN. Commercial preparations of recombinant IFN, obtained from expression in E. coli are deemed to be homogenous, however, it is not known whether this is also the result of purification by HPLC or use of another genetic tool where terminal N-acetylation is avoided. In a novel PEGylation of interferon α-2b at one of the disulphide bonds, the MALDI spectrum in the paper, of the precursor interferon α-2b, was shown to have a mass of 19,306 Da [5] which corresponds to N-acetyl-interferon α-2b (2, Figure 1 ) and not interferon α-2b itself that would have a mass of 19,265 Da. The interferon used in the latter work was reported to be obtained from a yeast expression system. The specificities of yeast N-acetyl transferases have been studied, using a panel of proteins but in no case Cys modification was observed [10] . It would thus appear that a specific, but unknown, signal in interferon α-2b is recognized for acetylation by an acetyl transferase in yeast as well as E. coli.
Expression of the gene for Met-Phe-IFN (3): analysis of the protein and of its tryptic peptides
In order to avoid the heterogeneity, our subsequent efforts were aimed to use of an N-terminal sequence that was not susceptible to the action of methionine aminopeptidase. Here, we took advantage of our studies on the preparation of a variety of proinsulin derivatives. In general, these derivatives have a phenylalanine following the N-terminal methionine, that is, a Met-Phe sequence [11, 12] . In these derivatives we did not observe the removal of methionine or any other modification involving this residue.
In the light of these observations, interferon derivative containing Met-Phe was engineered, expressed in E. coli and the inclusion bodies solubilized at pH 11.00. We serendipitously discovered that use of pH 11 greatly improved the yield of the correctly folded protein compared to pH 8.0, used in our previous study [1] . Unlike the HPLC profile of the refolded Met-IFN ( Tryptic digestion of Met-Phe-IFN, without prior cleavage of the disulphide bonds, followed by ESI-MS analysis, showed the presence of 92% of the theoretically possible peptides including those containing the correct disulphide bonds (Table S4 and 
Expression of the genes for the chimeras 4, 5 and 6 (Figure 1): analysis of the proteins and of their tryptic peptides
Encouraged by the results on Met-Phe-IFN, we extended the use of this approach to fusion proteins involving interferon α-2b and cytochrome b5. The most well used partner for bioactive peptide drugs is human serum albumin. The choice of this protein has been justified for a variety of reasons [13, 14] and its use is exemplified by human serum albumin-interferon fusion proteins [6, 7, [15] [16] [17] , which are typically expressed in yeast [15] . The expression of such proteins in E.
coli is problematic since serum albumin contains 35 cysteine residues engaged in 17 disulphide bonds. Since the putative conjugate of the protein with interferon will add four further cysteine residues, the possibility of the formation of native disulphide bonds within each partner will be greatly reduced. In order to avoid this complication we selected human cytochrome b5 as a fusion partner for interferon since it does not possess cysteine residues.
Three fusion proteins were designed. Two of these contained the native interferon α-2b sequence ligated either to the N-or the C-terminal of cytochrome b5 (4 and 6 respectively, Figure 1 ). In the third derivative, the sequence Met-Phe-IFN was placed at the cytochrome b5 N-terminal (5 Figure   1 ).
These fusion proteins were expressed in E. coli as inclusion bodies, which were solubilized and refolded as described for Met-Phe-IFN (3 Figure 1) . HPLC analysis of Met-IFN-b5-chimera (5 Figure 1 ) showed the presence of three peaks. From their masses these were characterized as: (a) the translation product of the encoding-DNA retaining the N-terminal methionine (peak 3, Figure   3 ), (b) where methionine had been removed (peak 1, Figure 3 ) and (c) in which the amino group of Cys residue had been acetylated (peak 2, Figure 3 ). The profile with Met-IFN-b5-chimera (5 With b5-IFN-chimera (6 Figure 1) , the tryptic digest contained besides the Cys 29 -Cys 138 fragment (II), the second disulphide-bond-fragment (IV, Figure S3d , section 6), which as expected, had sequences from the C-terminal of b5 as well as N-terminal of IFN. Thus, using the oxidativerefolding conditions used in this work, the interferon motif underwent correct refolding, tolerating the extensions on either end of the molecule.
[ Figure 6 near here] 
Antiviral activities of the various derivatives of interferon
The SDS-PAGE profiles of all the five interferon derivatives (2-6 Figure 1 ) are shown in Figure   6 . With the availability of 4 new derivatives (3-6) their antiviral activities were assayed using Figure 7 ) prepared in the present work had the same activity as a reference standard In the light of the profile in Figure 7 , the same five concentrations (0.0374, 0.374, 3.74, 37.4 and 374 pM) which gave a satisfactory spread of points across the curve in Figure   7 were selected for each construct. The anti-viral activity profile of each interferon derivative in Figure 8 shows that for four of the constructs (2, 4, 5, 6; figure 1 ) the experimental points, as expected, were satisfactorily spread over the curves, however, in the case of Met-Phe-IFN (3), the points were clustered towards the lower half of the curve, which indirectly points to the fact that this construct differs from others in having higher activity. This feature is also indicated by the observation that 3 at 0.0374 pM showed similar inhibitory effect (ca.52%) as Met-IFN (3) at 0.374 pM (ca. 49.4%). This trend was present at all concentrations. With the proviso that points in the curve for 3 are not broadly scattered, the comparison of the IC50 values in Table 1 indicates that this construct is around 8-fold more active than its comparator 2.
The fusion of cytochrome b5 at the amino-terminal of interferon (b5-IFN-chimera, 6, Figure 1) was advantageous over fusion at the carboxy-terminal (Met-IFN-b5-chimra, 4, Figure 1 ), since the former had 75% bioactivity, relative to the control, compared to 3% for the latter. This shows that an amino terminal, shielded by the b5 domain in b5-IFN-chimera enhances the biological activity of the interferon domain. This trend of enhancing the biological activity by a stable Nterminal appendage is further shown by the fact that the relative bioactivity of Met-Phe-IFN-b5-chimera (increased to 33% from 1.3% for its comparator). The only difference between the two molecules is the presence after the initiator Met of Phe, which protects the N-terminal against the action of a peptidase. The nearly 8-fold increase in activity for construct 2 versus 3 parallels 11
fold that of 4 versus 5; the difference in both cases is the replacement of N-terminal Met for MetPhe, which improves activity in both cases. Table 1 . Relative bioactivities of recombinant interferon and its derivatives prepared in this study and those reported in literature. Numbers in parenthesis refer to structures in Figure 1 .The IC50values were determined using the online software "IC50 toolkit (ic50.tk)" http://www.ic50.tk/ and counter checked by the GraphPad prism7 ® software. International units were calculated as described in the Experimental Section. International units (IU) for the constructs g, h and i were calculated from % bioactivity, relative to interferon α-2b, reported in [13] and for j and k in [15] . According to Huang et al. [15] a fusion protein between human serum albumin and interferon α-2b (rHSA/IFNα2b) has 1.4% relative bioactivity when compared on molar basis to unmodified interferon. A second fusion construct of interferon β and albumin was estimated from the IC50 values to have 10% of the antiviral activity compared to interferon β [17] . Of all the fusion proteins reported in the literature PEG-intron (12-kDa polyethylene glycol moiety conjugated to interferon α-2b) was the most active having 35% of the activity of interferon α-2b (Table 1 ). Our comparison of the relative bioactivities of the molecules that we have developed has shown that fusion of interferon with cytochrome b5 at its amino terminal, (b5-IFN-chimera, 6, Figure 1 ), gives the most active fusion protein; 75% of the activity of interferon α-2b. It is interesting to note that the molecular mass of PEG-intron is very similar to that of b5-IFN-chimera. Furthermore, a simple addition of Met-Phe to the N-terminal of IFN (1a Figure 1) produces the highest specific activity antiviral protein with 8 fold enhancement over the native cytokine.
Sr
In Table 1 e (Met-Phe-IFN-b5-chimera) in Table 1 . We cannot tell whether the enhancement of the activity is due to stabilization of the N-terminal of the cytokine, by having a peptidase resistant motif, or that the Met-Phe sequence improves receptor binding. However, that the former may be the case is indicated by the comparison of the relative activities of proteins carrying the interferon domain either at the N-or C-terminal. Construct 6 containing the b5 appendage at the N-terminal is nearly 2.2 times more active than IFN with b5 at the C-terminal. Such a behavior is likely explained by b5 protecting the interferon from degradation initiated from its N-terminus.
Materials and Methods
Construction of Interferon derivatives
Interferon derivatives were engineered using two plasmids: pET-met-ifn, which contained the human interferon α-2b gene, cloned in the pET-21a expression vector [1] and a pT7-7 derivative, harbouring the complete gene for the membrane-bound form of human cytochrome b5 (a gift from
Mrs Monika Akhtar, Biological Sciences, University of Southampton, UK). T7-promoter and
ChimR2 primers (Table S1 , supplementary) were used for PCR amplification of the soluble domain of cytochrome b5. As illustrated in Figure S1 , fusion of interferon and b5 domains were achieved by placing a XhoI site in between the two domains thus making it possible to stitch the interferon DNA either N-or C-terminal to the cytochrome b5 DNA. This feature added two extra residues i.e. Leu Glu, at the junction of the two domains in the protein sequence (see 4-6 Figure   1 ). The derivatives containing Phe as the second residue, for example 3 and 5 ( Figure 1 ), were constructed using Phe-F1 primer (Table S2 , Supplementary). pTZ-57 R/T vector was used for cloning PCR amplified DNA fragments and the pET-21a vector was used for expression in this study. The derivatives generated in this study are tabulated in Table S3 , while Figures S1 A and B
(Supplementary) summarize the generalized approach adopted to generate the chimeric interferon derivatives.
Expression and purification of interferon derivatives
E. coli BL21 codon plus® harboring the appropriate plasmids were grown and inclusion bodies isolated as described previously [1] . It was found that solubilization of inclusion bodies at pH 11 had a beneficial effect on the proper folding and yield of native IFN as well as Met-Phe-IFN (1a and 3 Figure 1 respectively). Following is illustrative of the refolding procedure used for these constructs.
Inclusion bodies were suspended in a small volume of solubilization buffer (8 M urea, 50 mM Tris-HCl pH 8.0, 50 mM glycine), the mixture sonicated on ice, pH adjusted to pH-11.5 with NaOH to give a clear solution and volume made up to 5-7 mg of protein/ml using the solublization buffer. To the latter 4 mM DTT was added and the mixture incubated at 37 °C for 30 minutes to allow complete reduction of disulfide bridges, while the pH remained 11.5.
25 ml of the solubilized protein above (5 mg of protein /ml) was transferred to the refolding sink (250 ml, 100 mM Tris-HCl pH 8.0, 2 mM EDTA, 0.5 mM cysteine, 5 mM cystine, 0.1 mM PMSF) at a rate of 2.5 ml per hour; the final protein concentration in the refolding sink at the end of 10 hours was 0.5 mg/ml and the urea concentration was 0.8 M ±0.2 M. During the latter operation, the reaction was gently stirred and maintained at 4 0 C; after 10 hours all the thiols had been lost but the pH remained at 8.0. The refolded sample was dialyzed against 20 mM Tris-HCl pH 8.0, with 4 buffer changes, each after 6 hours, and then the protein was quantified by measuring absorbance at 280 nm.
Q-sepharose column purification
Q-FF pre-filled 1 ml or 5 ml Q-sepharose columns (G.E, Healthcare®) were used depending on the amount of protein being purified. All the solutions were passed through the column with the to 60 percent of the starting inclusion bodies. For the identification of properly refolded proteins, tryptic digestion of various interferon constructs was performed as described in [1] and MALDI mass spectrometric analysis of fragment containing correct disulphide bridges was performed in linear positive mode as described previously [19] .
Bioassays for anti-viral activity of IFN and its derivatives
In order to measure interferon activity, we measured inhibition of VSV-G pseudotyped HIV-1 derived vector particles encoding GFP. The particles were generated in HEK-293T cells (described in Supplementary Materials) , using a three plasmid system comprising pMDG (encoding VSV-G envelope), p8.91 (encoding HIV-1 Gag-pol, Tat and Rev) and pCSGW (HIV-1 genome plasmid encoding GFP) [18] . THP-1 cells were infected with the pseudotyped particles in the presence or absence of the drug and infected cells measured by flow cytometry for GFP expression 72 hours later as detailed below.
THP-1 cells were grown to 70-80% confluence in RPMI -1640 medium containing 10% FBS. For each of the test sample a 12 well plate was used and the respective interferon sample (dissolved in solubilizing buffer comprising: NaCl, 7.2 mg/ml; Tween 20, 0.2 mg/ml; ammonium acetate 0.77mg/ml) was ten-fold serially diluted with DMEM, starting from 374 to 0.0374 fmol/ml (1000 U/ml to 0.1 U/ml in case of RoferonA), in 5 consecutive wells and one well left untreated with medium only. The aforementioned concentrations were used making the assumption that the specific activities of the test compounds on per mole basis will be similar to that of RoferonA (1.4×108 Units/mg or 2.66×1015 IU/mol) and the duplicate dilutions were made in next 6 wells.
In each well 10 5 cells were seeded and incubated overnight at 37 °C with 5% CO2 to provide ample time for the induction of antiviral state; the volume at this stage was 1000-900 µl. Next day 0. Figure S5 , supplementary material). The IC50 of a test derivative was taken to be equal to the number of units of RoferonA which produced 50% inhibition. For example, Figure 6 shows that the inhibition caused by 0.0071 ng (0.374 fmol) of Met-IFN, prepared in the present study, was
